[CAS NO. 85547-56-4] Piperaquine phosphate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [85547-56-4]

Catalog

HY-B1896A

Brand

MCE

CAS

85547-56-4

DESCRIPTION [85547-56-4]

Overview

MDL	-
Molecular Weight	633.51
Molecular Formula	C29H35Cl2N6O4P
SMILES	ClC1=CC=C2C(N3CCN(CCCN4CCN(C5=CC=NC6=CC(Cl)=CC=C56)CC4)CC3)=CC=NC2=C1.O=P(O)(O)O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Cell Rep. 2021 Apr 6;35(1):108959.

Summary

Piperaquine phosphate is a bisquinoline antimalarial agent. Piperaquine phosphate can be used in antimalarial research in combination with Artemisinin ^[1] ^[2] .

In Vivo

Piperaquine (10-90 mg/kg; a single i.p.) decreases parasitemia at all of the doses tested in mice ^[1] .
Piperaquine (90 mg/kg; a single i.p.) exhibits the t _1/2 , apparent clearance, and apparent volume of distribution 17.8 days, 33.5 mg•h/L, 1.55 L/h/kg, and 956 L/kg, respectively, in healthy mice and 16.1 days, 27.3 mg•h/L, 1.9 L/h/kg, and 1,059 L/kg in malaria-infected mice ^[1] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c mice (7 to 8 weeks) are inoculated with Plasmodium berghei parasites ^[1]
Dosage:	0, 10, 30, 90 mg/kg
Administration:	A single i.p. administration
Result:	The median survival time was 10 days at dose of 10 mg/kg. The median survival time was 54 days at dose of 30 mg/kg. All mice were active and alert and had stable body weights throughout the course of the study at dose of 90 mg/kg.

Animal Model:	Male Swiss mice (6 weeks old) ^[1]
Dosage:	90 mg/kg (Pharmacokinetic Analysis)
Administration:	A single i.p. administration
Result:	t _1/2 =17.8 d; AUC=33.5 mg•h/L; apparent clearance=1.55 L/h/kg; apparent volume of distribution=956 L/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05829187	Syamsudin Abdillah,Ph.D, Pharm D\|Apt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati, M.Clin, Pharm, Ph.D\|Pancasila University	Uncomplicated Plasmodium Falciparum	November 1, 2022	Phase 2
NCT01899820	Sabah Ahmed Omar\|World Bank\|Kenya Medical Research Institute\|KEMRI-Wellcome Trust Collaborative Research Program	Malaria	April 2013	Phase 3
NCT02434952	Malaria Consortium\|National Centre for Parasitology, Entomology and Malaria Control, Cambodia\|Institute Pasteur, Cambodia\|World Health Organization\|Centers for Disease Control and Prevention	Malaria, Falciparum\|G6PD Deficiency	October 2014	Phase 4
NCT02431637	Medicines for Malaria Venture\|Q-Pharm Pty Limited\|Clinical Network Services (CNS) Pty Ltd\|Sullivan Nicolaides Pathology\|QIMR Berghofer Medical Research Institute\|Army Malaria Institute, Australia	Malaria	April 2015	Phase 1
NCT01075945	University of Khartoum\|Southeast University, China	Malaria	February 2010	Phase 4
NCT02083380	Medicines for Malaria Venture	Uncomplicated Plasmodium Falciparum Malaria	July 2014	Phase 2\|Phase 3
NCT02836002	Radboud University Medical Center\|The PATH Malaria Vaccine Initiative (MVI)\|QIMR Berghofer Medical Research Institute	Malaria	June 2016	Phase 1\|Phase 2
NCT04844099	Liverpool School of Tropical Medicine\|University of Bergen\|University of Malawi\|Makerere University\|Indiana University\|Global Health Uganda LTD	Sickle Cell Anemia in Children\|Malaria	April 9, 2021	Phase 3
NCT00682578	University of Oxford\|Wellcome Trust\|Ministry of public Health Afghanistan	Uncomplicated Falciparum Malaria\|Vivax Malaria	July 2007	Phase 3
NCT04280692	University of Oxford\|KEMRI-Wellcome Trust Collaborative Research Program\|Sanaria Inc.\|Kenya Medical Research Institute	Malaria,Falciparum	August 22, 2022	Phase 1\|Phase 2
NCT01231880	Makerere University\|Bill and Melinda Gates Foundation	Malaria	February 2011	Phase 3
NCT03454048	Radboud University Medical Center\|The PATH Malaria Vaccine Initiative (MVI)\|QIMR Berghofer Medical Research Institute	Malaria,Falciparum\|Gametocytes\|Controlled Human Malaria Infection\|Transmission	May 7, 2018	Not Applicable
NCT02543086	Novartis Pharmaceuticals\|Medicine for Malaria Venture\|Novartis	Plasmodium Falciparum Malaria	July 2015	Phase 1
NCT05160363	Medicines for Malaria Venture\|Richmond Pharmacology Limited\|PharmaKinetic Ltd	Healthy	February 18, 2022	Phase 1
NCT04767191	Jhpiego\|Kenya Ministry of Health\|Centers for Disease Control and Prevention\|United States Agency for International Development (USAID)	Uncomplicated Malaria	March 15, 2021	Phase 4
NCT02184637	GlaxoSmithKline\|Medicines for Malaria Venture	Malaria, Vivax	July 31, 2014	Phase 1
NCT01280162	Armed Forces Research Institute of Medical Sciences, Thailand\|United States Army Medical Materiel Development Activity	Malaria	September 2010	Not Applicable
NCT05930782	Medicines for Malaria Venture	Malaria	July 2023	Phase 1
NCT01722539	Universiteit Antwerpen\|Fund for Scientific Research, Flanders, Belgium\|University of Kinshasa	Healthy	November 2012	Phase 3
NCT01651416	Centre for Global Health Research, Ghana\|London School of Hygiene and Tropical Medicine	Malaria\|Anaemia	July 2012	Phase 4
NCT01660022	Medicines for Malaria Venture\|Cross Research S.A.	Healthy	September 2012	Phase 1
NCT02974348	University of Bamenda\|Ministry of Science and Technology of the People´s Republic of China\|National Institute for Parasitic Disease, Chinese Center for Disease Control and Prevention	Drug Resistant Malaria Due to Plasmodium Falciparum	January 2013	Phase 3
NCT00529620	London School of Hygiene and Tropical Medicine\|Cheikh Anta Diop University, Senegal	Malaria	September 2007	Phase 3
NCT02575755	Papua New Guinea Institute of Medical Research\|The University of Western Australia\|University of Melbourne\|Malaria in Pregnancy Consortium	Pregnancy\|Infections, Plasmodia\|Drug Kinetics\|Clinical Efficacy	October 2012	Phase 4
NCT04660110	Makerere University	Malaria	January 28, 2021	Phase 3
NCT02199951	INDEPTH Network\|Ministry of Health, Ghana\|Ifakara Health Research and Development Centre\|Ministry of Health, Burkina Faso\|Centro de Investigacao em Saude de Manhica	Malaria	September 2013

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 17.86 mg/mL ( 28.19 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5785 mL	7.8925 mL	15.7851 mL
5 mM	0.3157 mL	1.5785 mL	3.1570 mL
10 mM	0.1579 mL	0.7893 mL	1.5785 mL

* Please refer to the solubility information to select the appropriate solvent.